Dyskinesia following modafinil administration in a patient with autism spectrum disorder and narcolepsy: a case report
Abstract
Background: In our clinical practice, we encountered a patient with autism spectrum disorder (ASD) and comorbid narcolepsy who developed dyskinesia following the administration of modafinil for excessive daytime sleepiness. Modafinil is widely prescribed as a wakefulness-promoting agent for the treatment of narcolepsy. Although dyskinesia has been reported as a potential adverse effect of modafinil, to our knowledge, no cases have been described in individuals with ASD. We hypothesized that modafinil contributed to the development of dyskinesia in this patient and conducted a literature review to explore the possible underlying mechanisms.
Case presentation: A 24-year-old Japanese woman with ASD was diagnosed with narcolepsy type 2. She had previously been treated with aripiprazole for ASD-related symptoms, but it had been discontinued more than two weeks before the sleep study. Modafinil was initiated at 100 mg/day and increased to 200 mg/day after three weeks because of insufficient efficacy. Two weeks after the dose increase, dyskinesia developed. A literature review was performed to identify potential mechanisms. Dyskinesia may have resulted from dysregulated striatal dopamine release associated with ASD and residual dopamine D2 receptor blockade from prior aripiprazole use, triggered by modafinil.
Conclusion: Dopaminergic agents in individuals with ASD may induce dyskinesia, particularly following dose escalation, underscoring the need for clinical vigilance.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.